key: cord-0849637-lnwe0r8p
authors: Huang, Zhiwei; Chai, Jijie
title: Door to the cell for COVID-19 opened, leading way to therapies
date: 2020-06-26
journal: Signal Transduct Target Ther
DOI: 10.1038/s41392-020-00215-6
sha: b5373bb304056efe9db4bb551e773c1cfa09fa16
doc_id: 849637
cord_uid: lnwe0r8p

nan

Structural comparison showed that the ACE2-bound SARS-CoV-2 RBD is nearly identical with that from the free SARS-CoV-2 spike protein, indicating that ACE2 binding induces no notable conformational changes in SARS-CoV-2 RBD.

Specific recognition of ACE2 by SARS-CoV-2 involves two β-sheets (β5 and β6) and three connecting loops of the RBM. Structural superimposition showed that SARS-CoV-2 RBD and SARS-CoV RBD employ a highly conserved mechanism for interaction with ACE2, supporting a close evolutionary relationship between the two viruses. Both of the RBM-ACE2 interfaces feature a large network of hydrogen bonds, highlighting specific interaction between the two proteins. Fourteen of the ACE2-interacting residues are shared by the two RBDs, of which 8 are identical and 5 are similar. The shared but non-conserved residue interacts with the same set of amino acids of ACE2. The conserved interactions in the SARS-CoV-2 RBM/ACE2 and SARS-CoV RBM/ACE2 complexes suggests that the two RBDs can have a similar affinity with ACE2. Indeed, quantification assays using surface plasmon resonance showed that SARS-CoV-2 RBD and SARS-CoV RBD bound to the ACE2 receptor with an affinity~4.7 and~31.0 nM, respectively. One notable difference between two complex structures is that Lys417 of SARS-CoV-2 is located outside the RBM but forms salt-bridge interactions with Asp30 of ACE2. By comparison, the equivalent position of SARS-CoV has a valine residue, which is unlikely to form the salt bridges seen in the SARS-CoV-2 RBD/ACE2 complex. This subtle structural difference was proposed to contribute to the slightly higher affinity between SARS-CoV-2 RBD and ACE2. However,~20-fold difference between SARS-CoV-2 (Kd of 14.7 nM for ACE2) and SARS-CoV (Kd of 325 nM for ACE2) in binding affinity with ACE2 was observed by another group, 4 probably due to different proteins used in the assays. The study by Lan et al. 1 also provided an explanation for the observation that none of the isolated SARS-CoV monoclonal antibodies are able to neutralize SARS-CoV-2. By mapping the epitope residues of SARS-CoV RBD onto the sequence of SARS-CoV-2 RBD, they found that one third (7 over 21) epitope positions of the antibody 80R are altered in SARS-CoV-2 RBD. A similar observation was also made with the epitope positions of the antibody m396.

Altogether, the study by Lan et al. 1 revealed the structural mechanism of ACE2 receptor recognition by SARS-CoV-2 RBD. The mechanism sheds light on pathogenesis of the highly pathogenic virus and can serve as a template for developing intervention strategies targeting SARS-CoV-2 spike and receptor recognition. It is unexpected that SARS-CoV-2 and SARS-CoV employ a nearly identical mechanism for interaction of the ACE2 receptor, given 

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Structure, function, and evolution of coronavirus spike proteins

Angiotensin-converting enzyme 2 is afunctional receptor for the SARS coronavirus

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/.